Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,752 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the transaction, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at $3,941,955. The trade was a 10.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $245.44 on Friday. The firm has a market cap of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock’s fifty day moving average price is $267.01 and its 200-day moving average price is $248.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The company’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. American Trust purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $309,000. Tidal Investments LLC grew its stake in Alnylam Pharmaceuticals by 75.1% in the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company’s stock valued at $5,650,000 after purchasing an additional 8,811 shares during the last quarter. Sanctuary Advisors LLC grew its stake in Alnylam Pharmaceuticals by 91.8% in the third quarter. Sanctuary Advisors LLC now owns 4,558 shares of the biopharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 2,181 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in Alnylam Pharmaceuticals by 4.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 34,713 shares of the biopharmaceutical company’s stock valued at $9,547,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in Alnylam Pharmaceuticals by 27.3% in the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock valued at $4,254,000 after purchasing an additional 3,315 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ALNY. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the company from $198.00 to $370.00 in a research report on Friday, August 16th. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Bank of America increased their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.